⏳ Fetching live dividend data...
Home › Calculator › BIOGF Dividend Calculator 2026
Biocartis Group N.V. · OTC
Price: $0.66 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Click to apply scenario to the calculator
Year your monthly dividend income covers each expense (based on current settings)
$10,000 in BIOGF → $35.88M in 10 years · $245,992.47/month
Biocartis Group N.V. is a molecular diagnostics firm dedicated to advancing clinical practice through innovative diagnostic solutions. These offerings aim to benefit patients, clinicians, healthcare payers, and the wider healthcare industry, with a particular emphasis on the field of oncology. Central to their product portfolio is the proprietary Idylla platform, a real-time polymerase chain reaction (PCR) system. This cutting-edge technology delivers vital molecular information, which is instrumental in both selecting appropriate treatments and continuously monitoring their effectiveness. The company provides a diverse array of Idylla tests, including mutation analyses for oncology biomarkers such as BRAF, KRAS, MSI, EGFR, and NRAS-BRAF. Beyond cancer diagnostics, they also offer panels for infectious diseases, specifically Idylla SARS-CoV-2/Flu/RSV and standalone SARS-CoV-2 tests. Additionally, their SeptiCyte RAPID test offers quick assessment of host response. For research purposes, Biocartis supplies various assays for detecting mutations, including those for MSI, KRAS, BRAF, ctEGFR, NRAS-BRAF-EGFR S492R, ctKRAS, EGFR, GeneFusion, ctBRAF, and ctNRAS-BRAF-EGFR S492R. Biocartis actively engages in strategic collaborations. They have partnered with Amgen to evaluate the Idylla RAS testing capabilities, aiming for rapid, decentralized diagnostics and faster access to crucial RAS biomarker data via the Idylla platform. Another collaboration with Bristol-Myers Squibb Company focuses on the regulatory approval and application of the Idylla MSI test in conjunction with immuno-oncology therapies. Furthermore, Biocartis holds a licensing, development, and commercialization agreement with GeneproDx for integrating the novel ThyroidPrint genomic test onto the Idylla platform. Founded in 2007, Biocartis Group N.V. operates from its headquarters located in Mechelen, Belgium.
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BIOGF position with:
Real after-tax yield depends on where you live and how you hold BIOGF.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 303.03% | 300.23% | $30,303 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 257.58% | 254.78% | $25,758 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 242.42% | 239.62% | $24,242 / yr |
| 🇬🇧 UK ISA | 0% | 303.03% | 300.23% | $30,303 / yr |
| 🇬🇧 UK Taxable | 8.75% | 276.51% | 273.71% | $27,651 / yr |
| 🇨🇦 TFSA | 0% | 303.03% | 300.23% | $30,303 / yr |
| 🇨🇦 CA Taxable | 25% | 227.27% | 224.47% | $22,727 / yr |
| 🇦🇺 Super (pension) | 15% | 257.58% | 254.78% | $25,758 / yr |
| 🇦🇺 AU Taxable | 30% | 212.12% | 209.32% | $21,212 / yr |
| 🇩🇪 DE Taxable | 26.375% | 223.11% | 220.31% | $22,311 / yr |
| 🇫🇷 FR Taxable | 30% | 212.12% | 209.32% | $21,212 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
BIOGF pays quarterly — 4 times per year. Next ex-div: TBD.
How BIOGF compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BIOGF sourced from FMP /financial-growth endpoint — real data, not estimates.
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BIOGF dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Biocartis Group N.V. (BIOGF) is currently trading at $0.66, trading near its 52-week low. The current dividend yield is 303.03% based on an annual payout of $2.00 per share.
Biocartis Group N.V. (BIOGF) is a healthcare stock currently trading at $0.66 with a dividend yield of 303.03%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
Auto-generated from live market data. For educational purposes only — not financial advice.
Real users. No sign-up required to leave a review.
“Finally a free dividend calculator that doesn't make me sign up or connect my brokerage. Entered SCHD and got the full DRIP projection in seconds. Bookmarked immediately.”
“I've been trying to figure out how much dividend income I'd need to retire. This tool showed me exactly — $400K in JEPI at 7% yield gives me $2,333/month. No calculator did that this clearly before.”
“Really solid passive income calculator. Covers everything: DRIP compounding, Roth IRA tax savings, DCA contributions. The year-by-year breakdown is what I was missing from other tools.”
“As someone planning retirement in 5 years, this dividend yield calculator showed me I need about 12% more in dividend stocks to hit my income target. Incredibly useful and completely free.”
“The Congress trades tracker is genius. Saw that several senators were buying O (Realty Income) and immediately ran it through the DRIP calculator. Bought 50 shares the next day.”
Reviews reflect users' personal experiences. Not financial advice.
Leave a review →If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.
⏱️ Takes 30 seconds · No signup · Free forever